Dermata Therapeutics, Inc. (NASDAQ:DRMAW) Short Interest Update

Dermata Therapeutics, Inc. (NASDAQ:DRMAW) was the target of a large growth in short interest during the month of April. As of April 15th, there was short interest totalling 11,000 shares, a growth of 15.8% from the March 31st total of 9,500 shares. Based on an average daily volume of 5,100 shares, the short-interest ratio is currently 2.2 days.

Dermata Therapeutics Stock Up 3.3 %

Shares of NASDAQ DRMAW traded up $0.00 during midday trading on Monday, reaching $0.01. 3,000 shares of the stock traded hands, compared to its average volume of 10,067. The company’s 50 day moving average is $0.01 and its 200 day moving average is $0.01. Dermata Therapeutics has a one year low of $0.01 and a one year high of $0.04.

About Dermata Therapeutics

Dermata Therapeutics, Inc, a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea.